Patent ID: 6384198
Filing Date: 2002-05-07
Classification: A61K,A61P,C07K

Abstract:
A method for inhibiting the production of HIV-1 in HIV-1 infected PBMC consistenly essentially of the steps of:(a) selecting and isolating PBMC infected with HIV-1; and (b) contacting said infected PBMC with at least one antibody or ligand in a quantity sufficient to inhibit the production of HIV-1 in said T cells, wherein said antibody or ligand is selected from the group consisting of: (i) an antibody selected from the group consisting of: (1) an antibody having specific binding affinity for CD2 antigen selected from the group consisting of single-chain recombinant antibody CD2 SFv-IG produced by expression of the construct cloned in recombinant Escherichia coli culture NO. ATCC 69277, an antibody having complementarity-determining regions identical with those of CD2 SFv-Ig, and an antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig; (2) another antibody to CD2 that is a monoclonal antibody; (3) a monoclonal antibody to CD18; (4) a monoclonal antibody to counter-receptor LFA-3; and (5) a monoclonal antibody to counter-receptor ICAM-1; and (ii) a LFA-3 ligand comprising the extracellular domain of LFA-3 in soluble form.